Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE vs ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
Fexofenadine is a selective peripheral H1-receptor antagonist; pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Moderate to severe pain where an opioid analgesic is appropriate
Relief of symptoms associated with seasonal allergic rhinitis and nasal congestion in adults and children 12 years and older
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
Adults and children 12 years and older: 1 tablet (fexofenadine 60 mg/pseudoephedrine 120 mg) orally every 12 hours with water. Do not exceed 2 tablets in 24 hours.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
Fexofenadine: 14.4 hours in healthy adults (range 11-15 h); pseudoephedrine: 5-8 hours (p H-dependent urinary excretion may prolong to 14-16 h in alkaline urine).
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Fexofenadine is minimally metabolized by the liver (≤5% via CYP3A4); pseudoephedrine is partially metabolized by hepatic N-demethylation and undergoes renal excretion.
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
Fexofenadine: 95% excreted unchanged in feces (biliary) and 5% in urine. Pseudoephedrine: 90% excreted unchanged in urine; remainder undergoes hepatic N-demethylation.
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
Fexofenadine: 60-70% bound to plasma proteins (albumin and α1-acid glycoprotein). Pseudoephedrine: negligible binding (<5%).
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
Fexofenadine: 3.3 L/kg (large Vd, extensive tissue distribution); pseudoephedrine: 2.6-3.5 L/kg (distributes into body water).
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
Fexofenadine: 33% oral bioavailability (first-pass effect minimal, but absorption incomplete). Pseudoephedrine: ~90% oral bioavailability.
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
Contraindicated in severe renal impairment (Cr Cl < 30 m L/min). For mild to moderate impairment (Cr Cl 30-80 m L/min): fexofenadine dose adjustment recommended (not to exceed 60 mg once daily), but pseudoephedrine accumulation may occur; use alternative product. Not studied in ESRD.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); caution.
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
Children under 12 years: not recommended. For children ≥12 years: same as adult dosing: 1 tablet every 12 hours with water.
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
Elderly patients may be more sensitive to CNS effects and anticholinergic effects of pseudoephedrine. Not recommended due to increased risk of adverse reactions; consider alternative therapy. If used, monitor closely.
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
None.
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Cardiovascular effects: hypertension, arrhythmias, palpitations, tachycardia, myocardial infarction, stroke (especially with pre-existing cardiovascular disease or concomitant use with other sympathomimetics).,Central nervous system stimulation: nervousness, dizziness, insomnia, tremor, seizures (may be exacerbated in patients with seizure disorders).,Increased intraocular pressure: contraindicated in narrow-angle glaucoma.,Urinary retention: use with caution in patients with prostate hypertrophy or obstructive uropathy.,Thyroid disorders: may aggravate hyperthyroidism; use with caution.,Diabetes mellitus: may increase blood glucose; monitor in diabetic patients.,Acute allergic reactions: discontinue if severe hypersensitivity occurs.,Renal impairment: fexofenadine clearance reduced; avoid use in severe renal impairment (Cr Cl <30 m L/min).,Elderly: more sensitive to adverse effects; use with caution.,Drug interactions: MAO inhibitors (hypertensive crisis); antihypertensives (reduced effect); alcohol/CNS depressants (additive effects).
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
Hypersensitivity to fexofenadine, pseudoephedrine, or any component of the formulation.,Severe hypertension or coronary artery disease.,Narrow-angle glaucoma.,Urinary retention (e.g., due to bladder neck obstruction or prostatic hyperplasia).,Severe renal impairment (Cr Cl <30 m L/min).,Concurrent use or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis).
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
Avoid alcohol, which can increase drowsiness. Grapefruit juice may reduce absorption of fexofenadine; avoid concurrent intake. Taking with high-fat meal may slow absorption but not affect overall efficacy.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
FDA Pregnancy Category C. First trimester: Animal studies show teratogenic effects at high doses of fexofenadine; pseudoephedrine may cause reduced uterine blood flow. Second and third trimesters: Risk of uterine contractions and fetal hypoxia due to pseudoephedrine vasoconstriction; avoid in preeclampsia.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
Fexofenadine: low excretion in breast milk (M/P ratio not established); pseudoephedrine: excreted in milk, may cause irritability and sleep disturbances in infants. Use caution, consider risk-benefit.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
No specific dose adjustments recommended; use lowest effective dose for shortest duration due to altered pharmacokinetics (increased plasma volume, decreased GFR).
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
Allegra-D 12 Hour contains fexofenadine (antihistamine) and pseudoephedrine (decongestant). Pseudoephedrine can cause insomnia, so advise taking the last dose early in the evening. Avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Use with caution in hyperthyroidism, diabetes, and prostatic hypertrophy. Do not exceed recommended dose; extended-release formulation must be swallowed whole.
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
Take this medication by mouth with or without food, usually every 12 hours.,Swallow the tablet whole; do not crush, chew, or break it.,Do not take more than 2 tablets in 24 hours.,Avoid taking at bedtime to prevent difficulty sleeping.,Do not take with other products containing pseudoephedrine or other decongestants.,Stop use and ask a doctor if symptoms do not improve within 7 days or are accompanied by fever.,Keep out of reach of children.
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE vs ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, answered by our medical review team.
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is a Antihistamine-Decongestant Combination that works by Fexofenadine is a selective peripheral H1-receptor antagonist; pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE and ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. The standard adult dose of ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is: Adults and children 12 years and older: 1 tablet (fexofenadine 60 mg/pseudoephedrine 120 mg) orally every 12 hours with water. Do not exceed 2 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE and ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show teratogenic effects at high doses of fexofenadine; pseudoephedrine may cause reduced uterine blood flow. Second and t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.